SINGAPORE, March 12, 2026 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization (CRO), today announced it has…
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with…
The recognition highlights Innovaccer's innovation leadership in transforming patient access through omnichannel, AI-powered engagement and workflow unification.SAN ANTONIO, March 2,…
HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has…
BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the…
The National Comprehensive Cancer Network pledges to update robust information resources for cancer patients and caregivers on an annual basis…
DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation from FDAClinical entry validates condensate modulator…
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform February 03, 2026 13:08 ET | Source:…
February 03, 2026 13:06 ET | Source: Restem Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L…
HYDERABAD, India, Jan. 31, 2026 /PRNewswire/ -- International Health Dialogue (IHD) 2026 opened today in Hyderabad, bringing together clinicians, patient…